A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome

American Journal of Medicine

Volumn 108, Issue 2, 2000, Pages 99-105

  De Meirleir, Kenny ^a   Bisbal, Catherine ^b   Campine, Isabelle ^a   De Becker, Pascale ^a   Salehzada, Tamim ^b   Demettre, Edith ^b   Lebleu, Bernard ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BIOCHEMICAL MARKER; RIBONUCLEASE;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DEPRESSION; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

ADENINE NUCLEOTIDES; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; MONOCYTES; OLIGORIBONUCLEOTIDES;

EID: 0033979461     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00300-9     Document Type: Article

References (33)

1. Holmes G.P., Kaplan J.E., Gantz N.M., et al. Chronic fatigue syndrome a working case definition . Ann Intern Med. 108:1988;387-389.
2. Fukuda K., Straus S.E., Hickie I., et al. The chronic fatigue syndrome a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group . Ann Intern Med. 121:1994;953-959.
3. Behan P.O., Behan W.M., Bell E.J. The postviral fatigue syndrome - an analysis of the findings in 50 cases. J Infect. 10:1985;211-222.
4. Buchwald D., Umali P., Umali J., et al. Chronic fatigue and the chronic fatigue syndrome prevalence in a Pacific Northwest health care system . Ann Intern Med. 123:1995;81-88.
5. Bates D.W., Schmitt W., Buchwald D., et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med. 153:1993;2759-2765.
6. Wesseley S., Chalder T., Hirsch S., et al. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome a prospective primary care study . Am J Pub Health. 87:1997;1449-1455.
7. Lloyd A.R., Hickie I., Boughton C.R., et al. Prevalence of chronic fatigue syndrome in an Australian population. Med J Aust. 153:1990;522-528.
8. Landay A.L., Jessop C., Lennette E.T., Levy J.A. Chronic fatigue syndrome clinical condition associated with immune activation . Lancet. 338:1991;707-712.
9. Buchwald D., Cheney P.R., Peterson D.L., et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med. 116:1992;103-113.
10. Chao C.C., Janoff E.N., Hu S.X., et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine. 3:1991;292-298.
11. Schluederberg A., Straus S.E., Peterson P., et al. NIH conference. Chronic fatigue syndrome research. Definition and medical outcome assessment. Ann Intern Med. 117:1992;325-331.
12. Buchwald D., Komaroff A.L. Review of laboratory findings for patients with chronic fatigue syndrome. Rev Infect Dis. 1991;S12-S18.
13. Jones J.F., Ray C.G., Minnich L.L., et al. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses elevated anti-early antigen antibodies . Ann Intern Med. 102:1985;1-7.
14. Miller G., Grogan E., Rowe D., et al. Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein-Barr virus infection. J Infect Dis. 156:1987;26-35.
15. Archard L.C., Bowles N.E., Behan P.O., et al. Postviral fatigue syndrome persistence of enterovirus RNA in muscle and elevated creatine kinase . J R Soc Med. 81:1988;326-329.
16. Yousef G.E., Bell E.J., Mann G.F., et al. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet. 1:1988;146-150.
17. DeFreitas E., Hilliard B., Cheney P.R., et al. Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci USA. 88:1991;2922-2926.
18. Swanink C.M., Melchers W.J., van der Meer J.W.M., et al. Enteroviruses and the chronic fatigue syndrome. Clin Infect Dis. 19:1994;860-864.
19. Sen G.C., Ransohoff R.M. Interferon-induced antiviral actions and their regulation. Adv Virus Res. 42:1993;57-102.
20. Bisbal C. RNase L effector nuclease of an activatable RNA degradation system in mammals . Prog Mol Subcell Biol. 18:1997;19-34.
21. Bisbal C., Martinand C., Silhol M., et al. Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway. J Biol Chem. 270:1995;13308-13317.
22. Martinand C., Salehzada T., Silhol M., et al. RNase L inhibitor (RLI) antisense constructions block partially the down regulation of the 2-5A/RNase L pathway in encephalomyocarditis-virus-(EMCV)-infected cells. Eur J Biochem. 254:1998;238-247.
23. Martinand C., Montavon C., Salehzada T., et al. RNaseL inhibitor is induced during HIV-1 infection and down regulates the 2-5A pathway in H9 cells. J Virol. 73:1999;290-296.
24. Horvath SE, Peterson DL, Suhadolnik RJ. Characterisation of RNase L dysfunction in peripheral blood mononuclear cell extracts from patients with chronic fatigue syndrome. Proceedings of the Fourth International AACFS Research & Clinical Conference on CFS, Boston, 1998:45.
25. Suhadolnik R.J., Reichenbach N.L., Hitzges P., et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis. 1994;S96-S104.
26. Suhadolnik R.J., Reichenbach N.L., Hitzges P., et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo. 8:1994;599-604.
27. Suhadolnik R.J., Peterson D.L., O'Brien K., et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res. 17:1997;377-385.
28. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 33:1990;160-172.
29. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Association, Washington, DC.
30. Bisbal C., Salehzada T., Lebleu B., Bayard B. Characterization of two murine (2′-5′)(A)n-dependent endonucleases of different molecular mass. Eur J Biochem. 179:1989;595-602.
31. Bayard B., Bisbal C., Lebleu B. Activation of ribonuclease L by (2′-5′)(A)4-poly(L-lysine) conjugates in intact cells. Biochemistry. 25:1986;3730-3736.
32. Wreschner D.H., Silverman R.H., James T.C., et al. Affinity labelling and characterization of the ppp(A2′p)nA-dependent endoribonuclease from different mammalian sources. Eur J Biochem. 124:1982;261-268.
33. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.